22 Nov 2019

CEO confident as Mereo BioPharma moves forward with pivotal Setrusumab study

Mereo’s CEO, Denise Scots-Knight, talks about setrusumab & the company’s plans for advancing to a paediatric pivotal trial for the treatment of Osteogenesis Imperfecta, based on setrusumab’s bone-building action & trends in fracture reduction shown in the Phase II b adult study.


About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates for rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo’s lead rare disease product candidate, setrusumab, is being developed for the treatment of osteogenesis imperfecta (OI) with topline 12-month results from a Phase 2b dose ranging study expected in Q4 2019. Mereo’s second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) with topline data expected in mid-2020.

Mereo’s broader pipeline consists of four additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”), leflutrozole for the treatment of hypogonadotropic hypogonadism (“HH”) in obese men, navicixizumab (for the treatment of platinum-resistant ovarian cancer, and etigilimab for patients with advanced or metastatic solid tumors.


+44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer

Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo)
+44 (0)20 7894 7000
Phil Davies
Will Goode

FTI Consulting (Public Relations Adviser to Mereo)
+44 (0)20 3727 1000
Simon Conway
Brett Pollard
Ciara Martin

Burns McClellan (US Public Relations Adviser to Mereo)
+01 (0) 212 213 0006
Lisa Burns
Steve Klass